Tuesday, September 4, 2012

PHA Message on FDA Decision Regarding Sildenafil (Revatio) for Pediatric Usage

The U.S. Food and Drug Administration (FDA) has issued a decision regarding sildenafil (Revatio) for pediatric usage. More information can be found in FDA’s Medwatch and Pfizer’s statements.

The FDA advises that patients and caregivers should NOT change the Revatio dose or stop taking Revatio without talking to a healthcare professional.

In addition, PHA’s Scientific Leadership Council will be releasing a statement in the near future. PHA is exploring the ramifications of this FDA ruling and the best way to support the pediatric PH community.


Anonymous said...

Neither link is working right now.

robert turner said...

Thanks for the knowledge you given . please provide the information of Sildenafil citrate as much as possible.